Lantheus to Acquire Life Molecular Imaging for an Upfront Payment of $350 Million to Accelerate Innovation for Patients in the Growing Alzheimer's Disease Radiodiagnostic Market

Acquisition Overview - Lantheus Holdings Inc announced a definitive agreement to acquire Life Molecular Imaging Ltd in an all-cash transaction consisting of an upfront payment of $350 million and up to an additional $400 million in potential earn-out and milestone payments [1] - The transaction is expected to close in the second half of 2025, subject to customary closing conditions including regulatory approvals [6] - The acquisition is expected to be accretive to Lantheus' Adjusted Earnings Per Share within 12 months of close [2] Strategic Rationale - The acquisition establishes a commercial Alzheimer's disease (AD) franchise with the addition of Neuraceq®, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer's Disease [1][2] - Life Molecular brings robust R&D capabilities, a strong commercial infrastructure, and an established international presence, which Lantheus plans to utilize to accelerate the development and commercialization of the combined company's pipeline [2] - The acquisition complements Lantheus' pipeline with the addition of highly complementary radiodiagnostic clinical-stage assets targeting diseases with significant unmet needs [4] Financial Impact - The transaction is expected to immediately enhance Lantheus' near and long-term growth profile [2] - Lantheus expects to maximize access to Neuraceq for the approximately 55 million people around the world who are living with AD or mild cognitive impairment [4] - The acquisition builds on Lantheus' June 2024 acquisition of the global rights to LMI's clinical-stage radiotherapeutic and radiodiagnostic pair, 177Lu-DOTA-RM2 and 68Ga-DOTA-RM2, which target gastrin-releasing peptide receptor (GRPR) for prostate, breast and other cancers [5] Product Details - Neuraceq is indicated for PET imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for AD and other causes of cognitive decline [13] - The overall safety profile of Neuraceq is based on data from 1,090 administrations of Neuraceq to 872 subjects, with no serious adverse reactions reported [10] - Neuraceq is commercially approved in the United States, Canada, Europe, the UK, Switzerland, China, Japan, South Korea, and Taiwan [20] Company Background - Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes [15] - Life Molecular Imaging is a global radiopharmaceutical company dedicated to developing and offering novel cutting-edge radiopharmaceuticals that improve early detection and characterization of chronic and life-threatening diseases [19] - Life Healthcare, the parent company of Life Molecular, is a global people-centered, diversified healthcare organization with over 40 years' experience in the South African private healthcare sector [11]